Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Chugai Pharmaceutical Co Ltd ADR

Healthcare US CHGCY

23.26USD
-0.18(0.77%)

Last update at 2026-06-22T19:31:00Z

Day Range

23.1923.69
LowHigh

52 Week Range

20.0634.84
LowHigh

Fundamentals

  • Previous Close 23.44
  • Market Cap92533.83M
  • Volume35122
  • P/E Ratio33.71
  • Dividend Yield3.17%
  • EBITDA631367.99M
  • Revenue TTM1257940.98M
  • Revenue Per Share TTM382.20
  • Gross Profit TTM 894250.98M
  • Diluted EPS TTM0.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 626788.28M 543034.00M 443821.00M 531166.00M 419385.00M
Minority interest - - - - -
Net income 455052.61M 387317.00M 325472.00M 374429.00M 302995.00M
Selling general administrative 116461.00M 110098.00M 112857.00M 23611.00M 25824.00M
Selling and marketing expenses - 110098.00M 112580.00M 77149.00M 76592.00M
Gross profit 937603.69M 831202.00M 698061.00M 783695.00M 661612.00M
Reconciled depreciation - - - - -
Ebit 627864.02M 542002.00M 439174.00M 533309.00M 421897.00M
Ebitda 661976.30M 573667.00M 470914.00M 531227.00M 419433.00M
Depreciation and amortization 34112.28M 31665.00M 31740.00M -2082.00000M -2464.00000M
Non operating income net other - - - - -
Operating income 618804.11M 542002.00M 439174.00M 533309.00M 421897.00M
Other operating expenses 700121.03M 628609.00M 672193.00M 726637.00M 577862.00M
Interest expense 1075.74M 1027.00M 27.00M 61.00M 48.00M
Tax provision 163794.00M 155717.00M 133602.00M 156737.00M 116390.00M
Interest income - 5.00M - - -
Net interest income -1026.00000M 1032.00M 3007.00M -9.00000M 28.00M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 171734.62M 155717.00M 118349.00M 156737.00M 116390.00M
Total revenue 1318925.14M 1170611.00M 1111367.00M 1259946.00M 999759.00M
Total operating expenses 318799.58M 289200.00M 258887.00M 250386.00M 239715.00M
Cost of revenue 381321.45M 339409.00M 413306.00M 476251.00M 338147.00M
Total other income expense net 7984.17M 1032.00M 4647.00M -2143.00000M -2512.00000M
Discontinued operations - - - - -
Net income from continuing ops 434012.00M 387317.00M 336745.00M 374429.00M 302995.00M
Net income applicable to common shares - - - 374429.00M 302995.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2470280.15M 2208373.00M 1932547.00M 1869758.00M 1538694.00M
Intangible assets 54576.23M 17868.00M 19860.00M 25141.00M 21974.00M
Earning assets - - - - -
Other current assets 41130.06M 35375.00M 35072.00M 26941.00M 26844.00M
Total liab 443163.31M 306874.00M 306967.00M 445371.00M 350677.00M
Total stockholder equity 2027114.84M 1901499.00M 1625580.00M 1424387.00M 1188017.00M
Deferred long term liab - - - - -
Other current liab 276245.45M 218639.00M 134951.00M 213895.00M 175156.00M
Common stock 73251.97M 73202.00M 73202.00M 73202.00M 73202.00M
Capital stock - - - - -
Retained earnings 1891332.21M 1746934.00M 1488738.00M 1293352.00M 1054050.00M
Other liab - - - 21641.00M 13765.00M
Good will - - - - -
Other assets - - - 121429.00M 56289.00M
Cash 426893.21M 540202.00M 458674.00M 222169.00M 267753.00M
Cash and equivalents - - - - -
Total current liabilities 411357.62M 290357.00M 288217.00M 423730.00M 327422.00M
Current deferred revenue - - 31.00M - -
Net debt -401165.66400M -529305.00000M -458674.00000M -222169.00000M -267753.00000M
Short term debt 7778.31M 6365.00M 6975.00M - -
Short long term debt - - - - -
Short long term debt total 25727.55M 10897.00M 13455.00M - -
Other stockholder equity 70562.13M 69896.00M 142557.00M -10973.00000M 1188017.00M
Property plant equipment - - - 386651.00M 352107.00M
Total current assets 1741946.31M 1606043.00M 1366426.00M 1336537.00M 1063661.00M
Long term investments - - - - -
Net tangible assets - - - 1399246.00M 1166043.00M
Short term investments 553471.56M 456143.00M 280308.00M 280938.00M 204217.00M
Net receivables 443414.48M 334256.00M 318892.00M 514283.00M 356009.00M
Long term debt - - - - -
Inventory 277036.99M 240067.00M 273480.00M 292206.00M 208838.00M
Accounts payable 127333.86M 65353.00M 112468.00M 209835.00M 152266.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8031.47900M 11467.00M -5715.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 97127.26M 69835.00M 64474.00M 335286.00M 246489.00M
Deferred long term asset charges - - - - -
Non current assets total 728333.85M 602330.00M 566121.00M 533221.00M 475033.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -100804.00000M -227365.00000M -65479.00000M -145994.00000M -47236.00000M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -214805.10600M -227365.00000M -37290.00000M -145994.00000M -118927.00000M
Net borrowings - - - -7599.00000M -7599.00000M
Total cash from financing activities -322362.31000M -141006.00000M -139331.00000M -145641.00000M -107408.00000M
Change to operating activities - - - -183311.00000M 43523.00M
Net income 455052.61M 589546.00M 325472.00M 575875.00M 470367.00M
Change in cash -112250.10500M 81528.00M 236505.00M -45584.00000M 55420.00M
Begin period cash flow 539143.32M 458674.00M 222169.00M 267753.00M 212333.00M
End period cash flow 426893.21M 540202.00M 458674.00M 222169.00M 267753.00M
Total cash from operating activities 408331.32M 447600.00M 409925.00M 244112.00M 279626.00M
Issuance of capital stock 142.00M 168.00M 179.00M 241.00M 322.00M
Depreciation 34112.28M - 31740.00M 31434.00M 30868.00M
Other cashflows from investing activities 30.41M 1099.00M 33679.00M 280.00M 133.00M
Dividends paid 313934.63M 133249.00M 131594.00M -138220.00000M -98644.00000M
Change to inventory - - - - -25500.00000M
Change to account receivables - - - - -85200.00000M
Sale purchase of stock -6.29100M -10.00000M -5.00000M -5.00000M -8.00000M
Other cashflows from financing activities -8570.27000M -7915.00000M -7949.00000M -7657.00000M 1.00M
Change to netincome - - - 21560.00M -97760.00000M
Capital expenditures 79970.66M 54899.00M 74258.00M 71239.00M 72866.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -83512.42700M -28843.00000M 130634.00M -183311.00000M -83122.00000M
Stock based compensation - - 338.00M - -
Other non cash items 2678.86M -113103.00000M 17637.00M -148452.00000M -107619.00000M
Free cash flow 328360.66M 392701.00M 335667.00M 172873.00M 206760.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CHGCY
Chugai Pharmaceutical Co Ltd ADR		 -0.18 0.77% 23.26 33.71 29.85 0.07 7.20 10.79 22.70
LLY
Eli Lilly and Company		 3.51 0.32% 1102.08 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 2.90 1.27% 231.29 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 13.52 6.25% 230.01 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 1.42 0.81% 176.35 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Chugai Pharmaceutical Co Ltd ADR

Nihonbashi Mitsui Tower, Chuo, Japan, 103-8324

Key Executives

Name Title Year Born
Dr. Osamu Okuda Pres, CEO & Representative Director 1963
Mr. Toshiaki Itagaki Head of Fin. Supervisory Division, CFO, Exec. VP & Director 1960
Toshiya Sasai Exec. of Investor Relations Group & Corp. Communications Department NA
Masahiko Uchida Gen. Mang. of Corp. Communications Department NA
Mr. Shinji Hidaka Exec. VP and Head of Marketing & Sales Division NA
Mr. Tsunanori Sato VP and GM of Marketing & Sales Division NA
Mr. Yoshiyuki Yano Exec. VP & Head of HR Management Department NA
Mr. Junichi Ebihara Exec. VP NA
Dr. Yoshiaki Ohashi SVP & Full-time Audit Supervisory Board Member 1960
Mr. Tetsuya Yamaguchi Exec. VP and Head of Project & Lifecycle Management Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions